Wegovy®

Branded GLP-1. Weekly self-injection pen (Novo Nordisk)

FDA-approved GLP-1 receptor agonist for chronic weight management.

Dosing: Set by your prescriber and adjusted over time based on how you respond.

Best for: Patients whose insurance covers Wegovy® specifically and who want the branded product.

Key points

• FDA-approved for chronic weight management
• Pivotal STEP 1 trial reference: about 15% average total body weight loss at 68 weeks
• Routed through HELiXVi with clinician oversight

Considerations

• Insurance coverage varies significantly
• Same GI side effect profile as compounded semaglutide
• Prescription-only

Prescription treatment requires an online consultation with a licensed HELiXVi clinician. Individual results vary.

Start your free consultation right now

No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.

See the full weight loss program